| scholarly article | Q13442814 |
| P50 | author | Marcella Sarzotti-Kelsoe | Q48146031 |
| John R. Mascola | Q63302442 | ||
| David C. Montefiori | Q63302725 | ||
| P2093 | author name string | Michael S Seaman | |
| Robert T Bailer | |||
| Hongmei Gao | |||
| Kelli M Greene | |||
| Daniel A Ozaki | |||
| Christopher A Todd | |||
| Ellen Turk | |||
| Miroslawa Bilska | |||
| Chen-li Lin | |||
| P2860 | cites work | Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 |
| Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research | Q24651042 | ||
| LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assays | Q28743608 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 | ||
| Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies | Q33274285 | ||
| International network for comparison of HIV neutralization assays: the NeutNet report | Q33410826 | ||
| Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials | Q33470284 | ||
| Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies | Q33614365 | ||
| Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production | Q33827798 | ||
| Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines | Q33911935 | ||
| International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials | Q34150070 | ||
| Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories | Q34718060 | ||
| Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system | Q35060140 | ||
| Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites | Q35635418 | ||
| Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells | Q35903806 | ||
| Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials | Q36083337 | ||
| Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. | Q36496923 | ||
| Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination | Q37119451 | ||
| Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. | Q37275060 | ||
| Measuring HIV neutralization in a luciferase reporter gene assay | Q39914262 | ||
| Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. | Q40191379 | ||
| Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection | Q41429274 | ||
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 131-146 | |
| P577 | publication date | 2013-12-01 | |
| P1433 | published in | Journal of Immunological Methods | Q15755939 |
| P1476 | title | Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. | |
| P478 | volume | 409 |
| Q37656908 | A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes |
| Q92177853 | A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection |
| Q52352443 | A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. |
| Q89790335 | A bivalent, spherical virus-like particle vaccine enhances breadth of immune responses against pathogenic Ebola viruses in rhesus macaques |
| Q100755368 | A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch |
| Q35076748 | A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component |
| Q47551447 | A single, continuous metric to define tiered serum neutralization potency against HIV. |
| Q90663185 | Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates |
| Q64088191 | Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial |
| Q40245017 | An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques |
| Q98951945 | An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction |
| Q93131421 | Analytical Treatment Interruption after Short-Term Antiretroviral Therapy in a Postnatally Simian-Human Immunodeficiency Virus-Infected Infant Rhesus Macaque Model |
| Q33786443 | Antibody 10-1074 suppresses viremia in HIV-1-infected individuals |
| Q92204307 | Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization |
| Q37091564 | Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy |
| Q35073270 | Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved |
| Q39108751 | Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development |
| Q38683449 | Breaching peripheral tolerance promotes the production of HIV-1-neutralizing antibodies |
| Q92280921 | Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope |
| Q95628083 | Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein |
| Q91812746 | Broadly Neutralizing Antibodies against HIV: Back to Blood |
| Q61815651 | CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity |
| Q47095100 | Circulating Plasmablasts from Chronically Human Immunodeficiency Virus-Infected Individuals Predominantly Produce Polyreactive/Autoreactive Antibodies |
| Q59797645 | Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies |
| Q59090059 | Combination therapy with anti-HIV-1 antibodies maintains viral suppression |
| Q36878930 | Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk |
| Q36012177 | Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study |
| Q35760486 | Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost |
| Q89803119 | Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22) |
| Q54209545 | Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B/B' env molecular clones derived from infections in China. |
| Q57796335 | Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth |
| Q35788320 | Comprehensive Characterization of the Transmitted/Founder env Genes From a Single MSM Cohort in China |
| Q64106399 | Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting |
| Q54201379 | Controlling the replication of a genomically recoded HIV-1 with a functional quadruplet codon in mammalian cells. |
| Q28554907 | Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene |
| Q27644383 | Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env |
| Q37619109 | DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies |
| Q57285042 | Defining HIV-1 Envelope N-glycan Microdomains Through Site-specific Heterogeneity Profiles |
| Q41933100 | Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells |
| Q59661528 | Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity |
| Q90051695 | Differential Outcomes Following Optimization of Simian-Human Immunodeficiency Viruses From Clades AE, B and C |
| Q88486719 | Discovery and development of safe-in-man broad-spectrum antiviral agents |
| Q36105672 | Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies |
| Q93037487 | Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection |
| Q89748751 | Engineered immunogen binding to alum adjuvant enhances humoral immunity |
| Q37286064 | Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors |
| Q88985874 | Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 |
| Q40523184 | Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy |
| Q36081789 | Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization |
| Q52580309 | First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. |
| Q92204630 | Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity |
| Q60957354 | Full-Length Envelope Analyzer (FLEA): A tool for longitudinal analysis of viral amplicons |
| Q55356257 | Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. |
| Q34392963 | Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies |
| Q36294701 | Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C. |
| Q40657302 | Glycosylphosphatidylinositol Anchor Deficiency Attenuates the Production of Infectious HIV-1 and Renders Virions Sensitive to Complement Attack |
| Q38631751 | HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces Gp41 Antibody Immunodominance in Rhesus Macaques |
| Q41919287 | HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site |
| Q36736860 | HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses |
| Q39365785 | HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike |
| Q60913187 | HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design |
| Q64229272 | HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry |
| Q90171697 | HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes |
| Q41918753 | HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine |
| Q55190209 | HIV-1 inhibition in cells with CXCR4 mutant genome created by CRISPR-Cas9 and piggyBac recombinant technologies. |
| Q47254280 | HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies |
| Q59339672 | HIV-1 vaccine design through minimizing envelope metastability |
| Q40089181 | HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers |
| Q90440637 | HIV-2 Depletes CD4 T Cells through Pyroptosis despite Vpx-Dependent Degradation of SAMHD1 |
| Q35140001 | HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial |
| Q53682331 | High throughput generation and characterization of replication-competent clade C transmitter-founder simian human immunodeficiency viruses. |
| Q89857555 | Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies |
| Q98735474 | Histone H2A-Reactive B Cells Are Functionally Anergic in Healthy Mice With Potential to Provide Humoral Protection Against HIV-1 |
| Q89878877 | Identification of HIV-1 Envelope Mutations that Enhance Entry Using Macaque CD4 and CCR5 |
| Q89790825 | Immune checkpoint modulation enhances HIV-1 antibody induction |
| Q40409324 | Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice |
| Q40114912 | Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults |
| Q93033026 | Immunological Fingerprints of Controllers Developing Neutralizing HIV-1 Antibodies |
| Q34593647 | Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies |
| Q89764726 | Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies |
| Q36978467 | Importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy |
| Q61796303 | Improvement of antibody functionality by structure-guided paratope engraftment |
| Q35076711 | Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes |
| Q39113783 | Increased frequencies of CD8+CD57+ T cells are associated with antibody neutralization breadth against HIV in viraemic controllers |
| Q34791232 | Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes |
| Q35861276 | Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission |
| Q41941058 | Introduction to a Special Issue of the Journal of Immunological Methods: Building global resource programs to support HIV/AIDS clinical trial studies |
| Q35167400 | Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies |
| Q92400606 | Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual |
| Q90458832 | Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains |
| Q36239578 | Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting |
| Q40331385 | Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk |
| Q47550072 | Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques. |
| Q40178574 | Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals |
| Q40290511 | Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. |
| Q54230395 | Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. |
| Q55097658 | Multivalent Antigen Presentation Enhances the Immunogenicity of a Synthetic Three-Component HIV-1 V3 Glycopeptide Vaccine. |
| Q38648833 | Nef is secreted in exosomes from Nef.GFP-expressing and HIV-1-infected human astrocytes. |
| Q89548775 | Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization |
| Q52660832 | Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones. |
| Q47562235 | Neutralization tiers of HIV-1. |
| Q53693698 | Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. |
| Q47144668 | Novel Therapeutic Approach for Inhibition of HIV-1 Using Cell-Penetrating Peptide and Bacterial Toxins |
| Q35974269 | Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection |
| Q92519133 | Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs |
| Q39017459 | Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells |
| Q27644646 | Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design |
| Q91862911 | Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen |
| Q38659318 | Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments |
| Q92327047 | Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1 |
| Q33804531 | Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge |
| Q64084556 | Peptide Assembly on the Membrane Determines the HIV-1 Inhibitory Activity of Dual-Targeting Fusion Inhibitor Peptides |
| Q39167914 | Position effects influence HIV latency reversal |
| Q52673965 | Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. |
| Q93105589 | Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir |
| Q40043685 | Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design |
| Q35915764 | Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences |
| Q37741310 | Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy |
| Q38534943 | Prospects for a globally effective HIV-1 vaccine |
| Q58382355 | Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis |
| Q39393679 | Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial |
| Q90334800 | Rapid Germinal Center and Antibody Responses in Non-human Primates after a Single Nanoparticle Vaccine Immunization |
| Q58569712 | Recent progress in broadly neutralizing antibodies to HIV |
| Q30657338 | Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth |
| Q59355458 | Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117 |
| Q61814105 | Reprogramming the antigen specificity of B cells using genome-editing technologies |
| Q89467843 | Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody |
| Q59351843 | Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals |
| Q89857234 | Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines |
| Q90637089 | Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial |
| Q93035342 | Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial |
| Q47549492 | Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. |
| Q41019767 | Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults |
| Q92498017 | Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study |
| Q44536209 | Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. |
| Q101226253 | Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2 |
| Q36294727 | Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection |
| Q92049906 | Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes |
| Q59360638 | Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys |
| Q36446733 | Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site |
| Q35913867 | Structural Determinants for the Selective Anti-HIV-1 Activity of the All-β Alternative Conformer of XCL1. |
| Q59350200 | Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition |
| Q37376640 | Structural basis for membrane anchoring of HIV-1 envelope spike |
| Q94569673 | Structural basis of transmembrane coupling of the HIV-1 envelope glycoprotein |
| Q55447637 | Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. |
| Q36973948 | Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap |
| Q37069793 | Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates |
| Q49997190 | Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody |
| Q59352769 | Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs |
| Q34762224 | Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones |
| Q59353403 | Synthetic DNA delivery by electroporation promotes robust in vivo sulfation of broadly neutralizing anti-HIV immunoadhesin eCD4-Ig |
| Q58583636 | Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N-Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition |
| Q50137034 | Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses |
| Q59349744 | T = 4 Icosahedral HIV-1 Capsid As an Immunogenic Vector for HIV-1 V3 Loop Epitope Display |
| Q91838076 | TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes |
| Q102075320 | TZM-gfp cells: a tractable fluorescent tool for analysis of rare and early HIV-1 infection |
| Q92240525 | Tat IRES modulator of tat mRNA (TIM-TAM): a conserved RNA structure that controls Tat expression and acts as a switch for HIV productive and latent infection |
| Q92628205 | The Differential Anti-HIV Effect of a New Humic Substance-Derived Preparation in Diverse Cells of the Immune System |
| Q64885907 | The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models. |
| Q37469197 | Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques |
| Q37643792 | Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques |
| Q40005891 | Transient CD4+ T Cell Depletion Results in Delayed Development of Functional Vaccine-Elicited Antibody Responses |
| Q89514917 | Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal gp140-specific antibody responses in mice |
| Q90044905 | VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage |
| Q47200747 | Validation of an automated system for aliquoting of HIV-1 Env-pseudotyped virus stocks |
Search more.